Global Hepatitis C Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025

  • ID: 4431767
  • Report
  • Region: Global
  • Acute Market Reports
1 of 4

FEATURED COMPANIES

  • AbbieVie Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmith Kline Plc.
  • Merck & Co. Inc.
  • Schering AG
  • MORE
Hepatitis C Treatment Market - Growth, Future Prospects and Competitive Analysis, 2017 - 2025 the global hepatitis C treatment market was valued at US$ 25.02 Bn in 2016, and is expected to reach US$ 65.48 Bn by 2025, expanding at a CAGR of 11.3% from 2017 to 2025.

Market Insights

Hepatitis C is a liver disease caused by the hepatitis C virus causing both acute and chronic hepatitis; approximately 55-85% of hepatitis C affected persons develop chronic HCV infection. For the purpose of the study hepatitis C treatment market is classified on the basis of drug type such as interferons, ribavirin and direct acting antivirals (DAA). Interferons and ribavirin are generally given in combination to increase effectiveness of ribavirin against hepatitis C. It is estimated that DAA class will show highest market growth during forecast period due to safety and effectiveness over previous treatment approach. DAA directly act on the virus by inhibiting certain enzymes and proteins which are necessary for replication of the HCV virus and thus cause fewer side effects. Newly approved medications such as zepatier (elbasvir /grazoprevir), Epclusa (sofosbuvir /velpatasvir), Mavyret (glecaprevir and pibrentasvir) and Vosevi (sofosbuvir, velpatasvir and voxilaprevir) are expected to show significant market growth during forecast period. It is studied that currently, North America is dominating the global hepatitis C treatment market due to higher investment in drug development, large number of affected population, higher cost of medication, higher treatment awareness and upsurge in funding by the government agencies in healthcare system are major factors that driving the hepatitis C treatment market growth. On the other hand, due to increasing healthcare awareness and developing economic condition Asia Pacific would show significant hepatitis C treatment market growth.

Competition Assessment

The hepatitis C treatment market is observed to be highly competitive and comprises large number of players. However, the market is currently dominated by few players such as AbbieVie Inc., Bristol-Myers Squibb Company, Gilead Sciences Inc., GlaxoSmith Kline Plc., Janssen Pharmaceuticals Inc., Merck & Co. Inc., F. Hoffmann-La Roche AG, Schering AG, Vertex Pharmaceuticals and other.

Key Market Movements:
  • Factors such as presence of strong pipeline molecule, increase in number of target population, improved diagnostic techniques and easy availability of treatment medication are driving the growth of hepatitis C treatment market globally.
  • Poor patient compliance to medication in some countries and adverse effects associated with the prolong use of medication is negatively impacting market growth of hepatitis C treatment.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbieVie Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmith Kline Plc.
  • Merck & Co. Inc.
  • Schering AG
  • MORE
Chapter 1 Preface
1.1 Report Description
1.1.1 Purpose of the Report
1.1.2 Target Audience
1.1.3 USP and Key Offerings
1.2 Research Scope
1.3 Research Methodology
1.3.1 Phase I - Secondary Research
1.3.2 Phase II - Primary Research
1.3.3 Phase III - Expert Panel Review
1.3.4 Assumptions

Chapter 2 Executive Summary
2.1 Global Hepatitis C Treatment Market Snapshot
2.2 Global Hepatitis C Treatment Market, by Drug Type
2.3 Global Hepatitis C Treatment Market Share, by Geography, 2016 (Value %)

Chapter 3 Hepatitis C Treatment Market Analysis
3.1 Global Hepatitis C Treatment Market Overview
3.2 Market Dynamics
3.2.1 Market Drivers
3.2.2 Challenges
3.2.3 Opportunities
3.3 Pipeline Analysis of Hepatitis C Treatment Drugs
3.4 Global Epidemiology of Hepatitis C
3.5 Attractive Investment Proposition
3.6 Competitive Landscape of Key Players in Hepatitis C Treatment Market

Chapter 4 Global Hepatitis C Treatment Market, by Drug Type
4.1 Overview
4.2 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Drug Type
4.3 Top 3 Countries
4.4 Interferons
4.4.1 Peginterferon alfa-2a
4.4.2 Peginterferon alfa-2b
4.4.3 Interferon alfa-2b
4.5 Ribavirin
4.6 Direct-Acting Antivirals (DAA)
4.6.1 Protease Inhibitor (Paritaprevir, Simepravir, Grazoprevir)
4.6.2 Polymerase Inhibitors
4.6.3 Other Drugs

Chapter 5 Global Hepatitis C Treatment Market, By Geography
5.1 Preface
5.2 North America (U.S. & Canada)
5.2.1 North America Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.2.2 North America Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.3 Europe (U.K., Germany & Rest of Europe)
5.3.1 Europe Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.3.2 Europe Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.4 Asia Pacific (China, Japan and Rest of APAC)
5.4.1 Asia Pacific Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.4.1 Asia Pacific Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.5 Latin America (Brazil, Mexico and Rest of LATAM)
5.5.1 Latin America Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.5.2 Latin America Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)
5.6 Middle East and Africa (GCC and Rest of MEA)
5.6.1 Middle East and Africa Hepatitis C Treatment Market, by Drug Type, 2015- 2025 (US$)
5.6.2 Middle East and Africa Hepatitis C Treatment Market, by Country, 2015- 2025 (US$)

Chapter 6 Company Profiles
6.1 AbbieVie Inc.
6.2 Bristol-Myers Squibb Company
6.3 F. Hoffmann-La Roche AG
6.4 Gilead Sciences Inc.
6.5 GlaxoSmith Kline Plc.
6.6 Janssen Pharmaceuticals Inc.
6.7 Merck & Co. Inc.
6.8 Schering AG
6.9 Vertex Pharmaceuticals

List of Figures
Fig. 1 Hepatitis C Treatment Market: Research Methodology
Fig. 2 Global Hepatitis C Treatment Market, by Drug Type, 2016 (US$ Bn)
Fig. 3 Global Hepatitis C Treatment Market Share, by Geography, 2016 (Value %)
Fig. 4 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Geography, 2016
Fig. 5 Attractive Investment Proposition: Global Hepatitis C Treatment Market, by Drug type, 2016
Fig. 6 Global Peginterferon alfa-2a Market, 2015 - 2025 (US$ Bn)
Fig. 7 Global Peginterferon alfa-2b Market, 2015 - 2025 (US$ Bn)
Fig. 8 Global Interferon alfa-2b Market, 2015 - 2025 (US$ Bn)
Fig. 9 Global Ribavirin Market, 2015 - 2025 (US$ Bn)
Fig. 10 Global Protease Inhibitor Market, 2015 - 2025 (US$ Bn)
Fig. 11 Global Polymerase Inhibitors Market, 2015 - 2025 (US$ Bn)
Fig. 12 Global Other Drugs Market, 2015 - 2025 (US$ Bn)

List of Tables
Table 1 Market Positioning of Key Players in Global Hepatitis C Treatment Market
Table 2 Global Hepatitis C Treatment Market, by Drug Type, 2015 - 2025 (US$ Bn)
Table 3 Top 3 Countries in Global Hepatitis C Treatment Market, 2015 - 2025 (US$ Bn)
Table 4 Global Interferons Market in Hepatitis C Treatment, 2015 - 2025 (US$ Bn)
Table 5 Global Direct-Acting Antivirals (DAA) Market, 2015 - 2025 (US$ Bn)
Table 6 Global Hepatitis C Treatment Market, by Geography, 2015 - 2025 (US$ Bn)
Table 7 North America Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
Table 8 North America Hepatitis C Treatment Market, by Country, 2015 - 2025 (US$ Bn)
Table 9 Europe Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
Table 10 Europe Hepatitis C Treatment Market, by Country, 2015 - 2025 (US$ Bn)
Table 11 Asia Pacific Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
Table 12 Asia Pacific Hepatitis C Treatment Market, by Country, 2015 - 2025 (US$ Bn)
Table 13 Latin America Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
Table 14 Latin America Hepatitis C Treatment Market, by Country, 2015 - 2025 (US$ Bn)
Table 15 Middle East and Africa Hepatitis C Treatment Market, by Drug Type, 2015-2025 (US$ Bn)
Table 16 Middle East and Africa Hepatitis C Treatment Market, by Country, 2015 - 2025 (US$ Bn)
Table 17 AbbieVie Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 18 Bristol-Myers Squibb Company: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 19 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 20 Gilead Sciences Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 21 GlaxoSmith Kline Plc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 22 Janssen Pharmaceuticals Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 23 Merck & Co. Inc.: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 24 Schering AG: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Table 25 Vertex Pharmaceuticals: Company Snapshot (Business Description; Financial Information; Drug Position/Portfolio; News Coverage)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbieVie Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • GlaxoSmith Kline Plc.
  • Janssen Pharmaceuticals Inc.
  • Merck & Co. Inc.
  • Schering AG
  • Vertex Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll